Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database.

Date publication

octobre 2021

Journal

Breast (Edinburgh, Scotland)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PETIT Thierry , Dr LORGIS Véronique , Dr JOUANNAUD Christelle

Tous les auteurs :
Annonay M, Gauquelin L, Geiss R, Ung M, Cristol-Dalstein L, Mouret-Reynier MA, Goncalves A, Abadie-Lacourtoisie S, Francois E, Perrin C, Le Fel J, Lorgis V, Servent V, Uwer L, Jouannaud C, Leheurteur M, Joly F, Campion L, Courtinard C, Villacroux O, Petit T, Soubeyran P, Terret C, Bellera C, Brain E, Delaloge S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34624756

Résumé

Treatment and outcomes of patients with HER2-positive (HER2+) metastatic breast cancer (MBC) have dramatically improved over the past 20 years. This work evaluated treatment patterns and outcomes according to age.

Mots clés

Elderly, HER2, Metastatic breast cancer, Overall survival

Référence

Breast. 2021 Oct 1;60:138-146